Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes
An erratum to this article was published (Pituitary, 23 Aug 2026 ↗)
Authors' conclusion
Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.
Study context
- Population
- Patients with prolactinoma treated by a single surgeon, 2006–2024; 44 macroadenomas, 13 microadenomas, 2 giant adenomas; 28 with cavernous sinus invasion (Knosp grade 3–4)
- Participants
- 59 patients
- Exposure
- Presurgical dopamine agonist vs no presurgical dopamine agonists (DA)
- DA+n = 37
- DA-n = 22reference
- Outcome
- Correlation of CAB dose and duration with fibrosis (CVF)
Methodological detailssingle-surgeon
- Single-surgeon
Main finding
As reported in the abstract
Neither cabergoline (CAB) dose nor duration correlated with collagen volume fraction (CVF)
r2 < 0.01, p = NS
Observational data: associations, not effects.
Further findings
Presurgical CAB exposure
- Median cumulative CAB dose (range 5.4-6711)
- 79.3 mg
- Median duration of CAB (range 16-7830)
- 570 days
Remission at last follow-up
- In remission at last follow-up
- 52.5%
- Cavernous sinus invasion predicted remission (univariable OR)
- OR 10.3, p < 0.001
- Tumor size predicted remission (univariable OR)
- OR 6.6, p = 0.02
- Neither surgeon fibrosis assessment nor CVF independently predicted remission; cumulative CAB dose and duration did not predict remission
- In multivariable analysis no single factor remained significant
Original publication
Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. Pituitary. Published 12 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →